Multidrug-Resistant Candida auris Misidentified as Candida haemulonii: Characterization by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and DNA Sequencing and Its Antifungal Susceptibility Profile Variability by Vitek 2, CLSI Broth Microdilution, and Etest Method

Journal of Clinical Microbiology
Shallu KathuriaAnuradha Chowdhary

Abstract

Candida auris is a multidrug-resistant yeast that causes a wide spectrum of infections, especially in intensive care settings. We investigated C. auris prevalence among 102 clinical isolates previously identified as Candida haemulonii or Candida famata by the Vitek 2 system. Internal transcribed spacer region (ITS) sequencing confirmed 88.2% of the isolates as C. auris, and matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) easily separated all related species, viz., C. auris (n = 90), C. haemulonii (n = 6), C. haemulonii var. vulnera (n = 1), and Candida duobushaemulonii (n = 5). The in vitro antifungal susceptibility was determined using CLSI broth microdilution (CLSI-BMD), the Vitek 2 antifungal susceptibility test, and the Etest method. C. auris isolates revealed uniformly elevated fluconazole MICs (MIC50, 64 μg/ml), and an alarming percentage of isolates (37%) exhibited elevated caspofungin MICs by CLSI-BMD. Notably, 34% of C. auris isolates had coexisting elevated MICs (≥2 μg/ml) for both fluconazole and voriconazole, and 10% of the isolates had elevated coexisting MICs (≥2 μg/ml) to two additional azoles, i.e., posaconazole and isavuconazole. In contrast to reduced amphotericin B ...Continue Reading

References

Jan 13, 1999·Diagnostic Microbiology and Infectious Disease·M A PfallerA Bolmström
Mar 4, 2000·Journal of Clinical Microbiology·J XuT G Mitchell
Feb 6, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Mi-Na KimDong Wook Ryang
Jul 1, 2011·Journal of Clinical Microbiology·Wee Gyo LeeHee-Chang Jang
Sep 3, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·E De CarolisG Fadda
Sep 21, 2013·Emerging Infectious Diseases·Anuradha ChowdharyJacques F Meis
Dec 21, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A ChowdharyJ F Meis
Jun 26, 2014·Emerging Infectious Diseases·Rindidzani E MagoboNelesh P Govender

❮ Previous
Next ❯

Citations

Jan 27, 2016·Mycoses·Sarah Santos GonçalvesArnaldo Lopes Colombo
Feb 20, 2016·Emerging Infectious Diseases·João Nobrega de AlmeidaGil Benard
Sep 20, 2015·Medical Mycology·Michael A Pfaller, Mariana Castanheira
Sep 9, 2015·BMC Genomics·Sharanya ChatterjeeUtpal S Tatu
May 11, 2016·Expert Review of Clinical Pharmacology·Laura L KovandaWilliam W Hope
Oct 26, 2016·Antimicrobial Resistance and Infection Control·Silke SchelenzMatthew C Fisher
Jul 15, 2016·International Journal of Systematic and Evolutionary Microbiology·Matthias Sipiczki, Ratna Mohd Tap
Dec 19, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Cornelius J Clancy, M Hong Nguyen
Jun 6, 2017·The Journal of Infection·Turkiya Al-SiyabiBadriya Al'Adawi
Jan 26, 2016·Journal of Microbiological Methods·S DinarelliG Longo
Jan 31, 2017·Revista iberoamericana de micología·Alba Cecilia Ruiz GaitánJavier Pemán
May 19, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marwan M AzarVirginia M Pierce
Jul 8, 2017·Mycoses·Jalila MohsinAbdullah M S Al-Hatmi
Feb 7, 2018·Current Infectious Disease Reports·Ilan S Schwartz, Thomas F Patterson
Mar 31, 2018·Antimicrobial Resistance and Infection Control·Marie-Elisabeth BougnouxJean-Ralph Zahar
May 16, 2018·Annals of the New York Academy of Sciences·Jennifer Geddes-McAlister, Rebecca S Shapiro
Nov 22, 2017·Antimicrobial Agents and Chemotherapy·Ruvini U PathiranaMira Edgerton
Apr 11, 2018·Antimicrobial Agents and Chemotherapy·Milena KordalewskaDavid S Perlin
Nov 8, 2017·Expert Review of Anti-infective Therapy·Matthew William McCarthy, Thomas J Walsh
Nov 17, 2017·Clinical Microbiology Reviews·Anna Jeffery-SmithColin S Brown
May 20, 2018·Emerging Microbes & Infections·Xiaojuan WangGuanghua Huang
Jun 8, 2018·Current Opinion in Infectious Diseases·Katja SarisAndreas Voss
Nov 24, 2017·Journal of Clinical Microbiology·Emily S Spivak, Kimberly E Hanson
Aug 30, 2017·Antimicrobial Agents and Chemotherapy·Hamed FakhimHamid Badali

❮ Previous
Next ❯

Related Concepts

Related Feeds

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.